These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15143914)

  • 1. An extensive metabolizer with recurrent ulcer responding to high dose of lansoprazole.
    Higuchi K; Tanabe S; Koizumi W; Nakayama N; Sasaki T; Nagaba S; Saigenji K; Katada N
    Hepatogastroenterology; 2004; 51(57):774-6. PubMed ID: 15143914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
    Shirai N; Furuta T; Xiao F; Kajimura M; Hanai H; Ohashi K; Ishizaki T
    Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Okudaira K; Kajimura M; Hishida A
    Aliment Pharmacol Ther; 2005 Jul; 22(1):67-74. PubMed ID: 15963082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
    Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
    Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dosaging of proton pumps inhibitors].
    Brørs O
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2397-9. PubMed ID: 16998554
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
    Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
    Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress of tailor-made treatment of peptic ulcer].
    Aoyama N; Shirasaka D; Okumura K
    Nihon Rinsho; 2002 Jan; 60(1):174-81. PubMed ID: 11808330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of proton pump inhibitor on intragastric acidity and it relation to S-mephenytoin hydroxylase genetic polymorphism].
    Wang H; Nie YQ; Dai SJ; She QZ; Li YY
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):777-80. PubMed ID: 14636465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
    Roh HK; Kim PS; Lee DH; Tybring G; Sagar M; Park CS; Seensalu R; Bertilsson L
    Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):112-9. PubMed ID: 15447734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
    Takahashi K; Motohashi H; Yonezawa A; Okuda M; Ito N; Yamamoto S; Ogawa O; Inui K
    Ann Pharmacother; 2004 May; 38(5):791-4. PubMed ID: 15010519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
    Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
    J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.
    Ando T; Kato H; Sugimoto N; Nagao Y; Seto N; Hongo H; Kajikawa H; Isozaki Y; Shimozawa M; Naito Y; Yoshida N; Ishizaki T; Yoshikawa T
    Dig Dis Sci; 2005 Sep; 50(9):1625-31. PubMed ID: 16133961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis.
    Ohkusa T; Maekawa T; Arakawa T; Nakajima M; Fujimoto K; Hoshino E; Mitachi Y; Hamada S; Mine T; Kawahara Y; Nagai T; Aoyama N; Yoshida N; Tadokoro K; Chida N; Konda Y; Seno H; Shimatani T; Inoue M; Sato N
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1331-9. PubMed ID: 15932363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.